Integra LifeSciences (NASDAQ:IART) Shares Gap Up on Earnings Beat

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price gapped up before the market opened on Tuesday following a better than expected earnings announcement. The stock had previously closed at $10.65, but opened at $12.23. Integra LifeSciences shares last traded at $12.8580, with a volume of 353,721 shares.

The life sciences company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. The business had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The firm’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS.

Key Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 results beat expectations — EPS $0.54 vs. $0.41 est; revenue $391.9M vs. $381.8M est, showing modest year-over-year growth and operating momentum. Integra LifeSciences Reports First Quarter 2026 Financial Results
• Positive Sentiment: Full-year FY2026 EPS guidance raised to $2.40–2.50, above consensus (~$2.35), signaling management confidence in longer?term profitability despite near-term headwinds. FY2026 Guidance in Press Release
• Neutral Sentiment: Leadership transition announced — Stuart Essig named President & CEO and Michael McBreen appointed Chief Commercial Officer; this provides clarity on succession but will take time to assess strategic impact. Leadership Transition Announcement
• Negative Sentiment: Near-term guidance came in light — Q2 EPS guide $0.440–0.520 (consensus ~$0.53) and revenue guide $410M–$425M (consensus ~$425.3M), which could pressure near-term estimates and cap upside until mid?year results. Q2 Guidance in Press Release

Analysts Set New Price Targets

A number of research analysts recently commented on IART shares. Wells Fargo & Company raised Integra LifeSciences to a “hold” rating in a research note on Wednesday, March 18th. Citigroup reduced their target price on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research note on Wednesday, March 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. Truist Financial reduced their target price on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Finally, Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $14.20.

Institutional Trading of Integra LifeSciences

Several institutional investors have recently added to or reduced their stakes in IART. Rubric Capital Management LP boosted its position in Integra LifeSciences by 58.4% during the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock valued at $90,233,000 after buying an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY boosted its position in Integra LifeSciences by 57.5% during the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock valued at $26,767,000 after buying an additional 796,300 shares during the period. Invenomic Capital Management LP boosted its position in Integra LifeSciences by 78.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock valued at $13,115,000 after buying an additional 463,729 shares during the period. Kotler Kevin purchased a new stake in Integra LifeSciences during the fourth quarter valued at about $5,309,000. Finally, SG Americas Securities LLC purchased a new stake in Integra LifeSciences during the fourth quarter valued at about $4,722,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Trading Up 23.7%

The firm’s 50-day simple moving average is $10.09 and its 200-day simple moving average is $11.73. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66. The firm has a market capitalization of $1.03 billion, a PE ratio of -1.96 and a beta of 1.08.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.